(Bloomberg) -- Merck & Co. shaved the top end of its 2025 revenue guidance and failed to produce any standout sales beats for its medicines in the third quarter, adding to challenges the drugmaker is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback